(:GWPH)

Apr 28, 2021 08:00 pm ET
GW Pharmaceuticals recognised for leadership in prescription cannabis-based medicines with prestigious Queen’s Award for Enterprise in Innovation
GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), a world leader in discovering, developing and commercialising regulatory approved cannabis-based medicines, announces that it has received the Queen’s Award for Enterprise...
Apr 23, 2021 04:01 pm ET
GW Pharmaceuticals Shareholders Approve Acquisition by Jazz Pharmaceuticals
GW Pharmaceuticals plc (Nasdaq: GWPH) (GW) and Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (Jazz) today announced that GW’s shareholders voted to approve the acquisition of GW by a subsidiary of Jazz (or its nominee(s)) at the GW shareholder meetings...
Apr 20, 2021 06:30 am ET
GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures associated with tuberous sclerosis complex
GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines, today announces that the European Commission (EC) has approved the...
Apr 13, 2021 08:30 am ET
GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences to Present Data at the 2021 American Academy of Neurology (AAN) Annual Meeting
GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S. subsidiary Greenwich Biosciences, announced today that the company will present...
Mar 30, 2021 08:08 am ET
Halper Sadeh LLP Investigates the Following Mergers – COHR, PRSP, HWCC, GWPH; Shareholders are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Coherent, Inc. (NASDAQ: COHR) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating...
Mar 25, 2021 10:42 am ET
Moore Kuehn Encourages GWPH, GNPK, PMBC, and SPFR Investors to Contact Law Firm
Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.   Moore Kuehn may seek...
Feb 26, 2021 07:15 am ET
GW Pharmaceuticals receives positive CHMP opinion for EPIDYOLEX® (cannabidiol) for use as treatment of seizures associated with Tuberous Sclerosis Complex
GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines, today announces that the European Medicines Agency’s (EMA) Committee...
Feb 17, 2021 12:21 pm ET
INVESTIGATION ALERT: Halper Sadeh LLP Investigates the Following Companies on Behalf of Shareholders - PTVCA, AEGN, CATM, CHNG, GWPH, PS, SNCA
NEW YORK, Feb. 17, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Feb 16, 2021 07:00 am ET
GW Pharmaceuticals plc Reports Fourth Quarter and Year-End 2020 Financial Results and Operational Progress
GW Pharmaceuticals plc (Nasdaq: GWPH), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced financial results and operating progress for the fourth quarter and full-year ended...
Feb 12, 2021 08:00 pm ET
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of GW Pharmaceuticals plc - GWPH
NEW YORK, Feb. 12, 2021 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating GW Pharmaceuticals plc ("GWPH" or the "Company") (GWPH) relating to its proposed acquisition by Jazz Pharmaceuticals Public Limited Company. Under the terms of the agreement, GWPH shareholders are expected to receive $200.00 in cash and $20.00 worth of Jazz ordinary shares per GWPH share t
Feb 12, 2021 05:20 am ET
Halper Sadeh LLP Continues to Investigate the Following Mergers; Shareholders Are Encouraged to Contact the Firm - MGLN, BPFH, CMD, GWPH, SPWH, ALSK
NEW YORK, Feb. 12, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies:
Feb 06, 2021 08:53 am ET
INVESTIGATION ALERT: Halper Sadeh LLP Investigates VIE, HMSY, GWPH, FLIR; Shareholders Are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: Viela Bio, Inc. (NASDAQ: VIE) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its...
Feb 04, 2021 11:19 am ET
GW PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of GW Pharmaceuticals plc - GWPH
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of GW Pharmaceuticals plc (NasdaqGS: GWPH) to Jazz Pharmaceuticals plc (NasdaqGS: JAZZ). Under the terms of the proposed transaction, shareholders of GW will receive only $200.00 in cash and $20.00 in Jazz ordinary shares for each American Depositary Share (“ADS”) of GW that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Feb 04, 2021 10:17 am ET
Moore Kuehn Encourages FST, GWPH, HOL, and VIE Investors to Contact Law Firm
NEW YORK, Feb. 4, 2021 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.  Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies:
Feb 04, 2021 05:51 am ET
INVESTIGATION ALERT: Halper Sadeh LLP Investigates the Following Companies on Behalf of Shareholders - GWPH, VIE, FLIR, SNCA
NEW YORK, Feb. 4, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Feb 03, 2021 05:32 pm ET
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of GW Pharmaceuticals plc Buyout
Rigrodsky Law, P.A. announces that it is investigating GW Pharmaceuticals plc (“GW Pharmaceuticals”) (NASDAQ GM: GWPH) regarding possible breaches of fiduciary duties and other violations of law related to GW Pharmaceuticals’ agreement to be...
Feb 03, 2021 03:46 pm ET
SHAREHOLDER ALERT: WeissLaw LLP Investigates GW Pharmaceuticals plc
NEW YORK, Feb. 3, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of GW Pharmaceuticals plc ("GWPH" or the "Company") (NASDAQ: GWPH) in connection with the proposed acquisition of the Company by Jazz Pharmaceuticals Public Limited Company ("Jazz") (NASDAQ: JAZZ).  Under the terms of the merger agreement, Jazz will acquire GWPH in a mixed cash-and-stock transaction for $220.00 per American Depositary Share ("ADS"), in the form of $200.00 in cash and $20.00 in Jazz ordinary shares.  The proposed transa
Feb 03, 2021 01:25 pm ET
GWPH Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of GW Pharmaceuticals plc Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – GWPH
Halper Sadeh LLP, a global investor rights law firm, is investigating whether GW Pharmaceuticals plc (NASDAQ: GWPH) and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders in connection with the proposed sale of GW Pharmaceuticals to Jazz Pharmaceuticals plc for $200.00 in cash and $20.00 in Jazz ordinary shares for each GW American Depositary Share (ADS).
Feb 03, 2021 12:14 pm ET
GW PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of GWPH and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of GW Pharmaceuticals plc (NASDAQ: GWPH) breached their fiduciary duties or violated the federal...
Feb 03, 2021 08:31 am ET
Thinking about trading options or stock in GW Pharmaceuticals, Bristol-Myers Squibb, Aurora Cannabis, Alibaba, or Workday?
NEW YORK, Feb. 3, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GWPH, BMY, ACB, BABA, and WDAY.
Feb 03, 2021 06:30 am ET
Jazz Pharmaceuticals to Acquire GW Pharmaceuticals plc, Creating an Innovative, High-Growth, Global Biopharma Leader
DUBLIN and LONDON, Feb. 3, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and GW Pharmaceuticals plc (Nasdaq: GWPH) today announced the companies have entered into a definitive agreement for Jazz to acquire GW for $220.00 per American Depositary Share (ADS), in the form of $200.00 in cash and $20.00 in Jazz ordinary shares, for a total consideration of $7.2 billion, or $6.7 billion net of GW cash. The transaction, which has been unanimously approved by the Boards of Directors of both companies, is expected to close in the second quarter of 2021.
Jan 11, 2021 07:00 am ET
GW Pharmaceuticals Provides Preliminary Fourth Quarter and Full-Year 2020 Net Product Sales Results and 2021 Program Milestones
GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full year 2020 and...
Jan 05, 2021 07:30 am ET
GW Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference
GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that Justin Gover, GW’s Chief Executive Officer, will...
Dec 21, 2020 11:30 am ET
JAMA Neurology Publishes Phase 3 Study of EPIDIOLEX® (cannabidiol) Oral Solution in Patients with Seizures Associated with Tuberous Sclerosis Complex
GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S. subsidiary Greenwich Biosciences, announced today that...
Dec 07, 2020 07:00 am ET
GW Pharmaceuticals to Present at the 2020 Needham Virtual Epilepsy & Pain – Specialty CNS Therapeutics Conference
GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that the Company will present at the Needham Virtual...
Dec 01, 2020 08:30 am ET
Greenwich Biosciences to Present Data on EPIDIOLEX® (cannabidiol) Oral Solution at the American Epilepsy Society Annual Meeting
GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S. subsidiary Greenwich Biosciences, announced today that a variety of data, including...
Nov 30, 2020 07:32 am ET
GW Pharmaceuticals to Present at the Evercore ISI 2020 Healthcare Conference
GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that the Company will present at the Evercore ISI...
Nov 17, 2020 09:40 am ET
Findit Features Members Global WholeHealth Partners, WynCore and OTC Tip Reporter
ATLANTA, GA / ACCESSWIRE / November 17, 2020 / Findit, Inc. (OTC PINK:FDIT) owner of Findit.com, a full-service social networking platform which provides online marketing campaigns and tools for members to increase brand awareness through content creation and sharing, resulting in indexing in search engines is highlighting: Global WholeHealth Partners (OTC PINK:GWHP), WynCore and OTC Tip Reporter. These members currently have on going monthly marketing cam
Nov 13, 2020 08:30 am ET
Greenwich Biosciences to Present Analysis of Three Clinical Studies of Nabiximols for People with Multiple Sclerosis Related Spasticity at the American Academy of Physical Medicine and Rehabilitation
Greenwich Biosciences, U.S. subsidiary of GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, will present data from an...
Nov 09, 2020 07:30 am ET
GW Pharmaceuticals to Present at the Stifel 2020 Virtual Healthcare Conference
GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that the Company will present at the Stifel Virtual...
Nov 03, 2020 09:40 am ET
Should you invest in Alibaba, Charles Schwab, GW Pharmaceuticals, UnitedHealth Group, or Uber?
NEW YORK, Nov. 3, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BABA, SCHW, GWPH, UNH, and UBER.
Nov 03, 2020 07:30 am ET
GW Pharmaceuticals plc Reports Third Quarter 2020 Financial Results and Operational Progress
GW Pharmaceuticals plc (Nasdaq: GWPH), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced financial results and operating progress for the third quarter ended September 30, 2020....
Nov 03, 2020 07:15 am ET
GW Pharmaceuticals Initiates Pivotal Phase 3 Study of Nabiximols for Multiple Sclerosis-Associated Spasticity
GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S. subsidiary Greenwich Biosciences, today announced that the...
Oct 22, 2020 10:34 am ET
GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Third Quarter Ending September 30th, 2020 and Host Conference Call on November 3rd, 2020
GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on November 3rd,...
Oct 21, 2020 08:00 am ET
Greenwich Biosciences, Inc., a Subsidiary of GW Pharmaceuticals plc, Launches unspoken symphony, a Breakthrough Innovation Created for the US Epilepsy Community
Greenwich Biosciences, Inc., the US leader in the field of cannabinoid prescription medicines and subsidiary of GW Pharmaceuticals plc (Nasdaq: GWPH), today announced the launch of unspoken symphony, a web-based, image-recognition technology that...
Sep 23, 2020 03:54 am ET
GW Pharmaceuticals receives Australian Therapeutic Goods Administration (TGA) approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures in patients with two rare, severe forms of childhood-o
GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines, today announces that the Australian Therapeutic Goods Administration...
Sep 10, 2020 04:00 pm ET
Greenwich Biosciences to Present Data on Safety and Efficacy of Nabiximols in Persons with Multiple Sclerosis-Associated Spasticity at the Joint ACTRIMS-ECTRIMS Meeting, MSVirtual2020
GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S. subsidiary Greenwich Biosciences, today announced that...
Sep 10, 2020 04:00 pm ET
Greenwich Biosciences to Share Results of Cannabis Use Survey Conducted with the North American Research Committee on Multiple Sclerosis (NARCOMS) at Joint ACTRIMS-ECTRIMS Meeting, MSVirtual2020
GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S. subsidiary Greenwich Biosciences, will present results of...
Sep 10, 2020 07:00 am ET
GW Pharmaceuticals Announces the Appointment of David Gryska to its Board of Directors
GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines today announced the appointment of David Gryska to the Board of Directors. Mr. Gryska will also serve...
Sep 01, 2020 07:00 am ET
GW Pharmaceuticals to Present at Upcoming Investor Conferences
GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that Justin Gover, GW’s Chief Executive Officer, will...
Aug 06, 2020 04:00 pm ET
GW Pharmaceuticals plc Reports Second Quarter 2020 Financial Results and Operational Progress
GW Pharmaceuticals plc (Nasdaq: GWPH), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced financial results and operating progress for the second quarter ended June 30, 2020....
Aug 03, 2020 07:00 am ET
FDA Approves EPIDIOLEX® (cannabidiol) Oral Solution to Treat Seizures Associated with Tuberous Sclerosis Complex
GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with its U.S. subsidiary Greenwich Biosciences, Inc., today announced the U.S. Food and Drug...
Jul 23, 2020 07:00 am ET
GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Second Quarter Ending June 30th, 2020 and Host Conference Call on August 6th, 2020
GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on August 6th, 2020...
Jun 30, 2020 07:00 am ET
GW Pharmaceuticals Presents Nabiximols U.S. Development and Commercial Strategy
GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announces the Company’s strategy for bringing its pipeline product...
Jun 23, 2020 07:01 pm ET
GW Pharmaceuticals announces that EPIDYOLEX® (cannabidiol) has been reclassified by the UK Home Office as a Schedule 5 drug
GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines, today announces that the UK Home Office has reclassified EPIDYOLEX...
Jun 04, 2020 04:00 pm ET
GW Pharmaceuticals to Host Virtual Investor Event on Its Nabiximols U.S. Development Program and Market Opportunity
GW Pharmaceuticals plc (NASDAQ: GWPH, GW or the Company), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that the Company will host a virtual event for investors to provide a...
Jun 02, 2020 07:00 am ET
GW Pharmaceuticals to Present at the Goldman Sachs 41st Annual Global Healthcare Conference
GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that Justin Gover, GW’s Chief Executive Officer, will...
May 11, 2020 04:00 pm ET
GW Pharmaceuticals plc Reports First Quarter 2020 Financial Results and Operational Progress
GW Pharmaceuticals plc (Nasdaq: GWPH), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announces financial results for the first quarter ended March 31, 2020. “In the first quarter of...
May 01, 2020 07:00 am ET
GW Pharmaceuticals to Present at the Bank of America Healthcare Conference 2020
GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that Justin Gover, GW’s Chief Executive Officer, will...
Apr 21, 2020 02:04 pm ET
GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the First Quarter Ending March 31st, 2020 and Host Conference Call on May 11th, 2020
GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on May 11th, 2020...
Apr 21, 2020 08:05 am ET
Outlook Therapeutics Bolsters Clinical and Commercial Expertise with Two Key Appointments to Board of Directors
Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced it has...
Apr 06, 2020 09:00 am ET
GW Pharmaceuticals plc and Its U.S. Subsidiary Greenwich Biosciences, Inc. Announce That EPIDIOLEX® (cannabidiol) Oral Solution Has Been Descheduled And Is No Longer A Controlled Substance
GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid platform, along with its U.S....
Mar 31, 2020 07:00 am ET
GW Pharmaceuticals and Greenwich Biosciences Announce FDA Acceptance of sNDA Filing with Priority Review for EPIDIOLEX® (cannabidiol) in the Treatment of Seizures Associated with Tuberous Sclerosis Co
GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with its U.S. subsidiary Greenwich Biosciences, Inc., today announced that the U.S. Food and...
Mar 13, 2020 07:00 am ET
GW Pharmaceuticals submits Type II Variation Application to the European Medicines Agency (EMA) to expand the use of EPIDYOLEX®, (cannabidiol) oral solution, for the treatment of seizures associated w
GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), a world leader in discovering, developing and commercialising cannabinoid prescription medicines, today announces the submission of a Type II Variation Application to the...
Mar 02, 2020 11:14 am ET
JAMA Neurology Publishes Results from Positive Phase 3 Trial of EPIDIOLEX® (cannabidiol) oral solution in Children with Seizures Associated with Dravet Syndrome
GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S. subsidiary Greenwich Biosciences, announced today that...
Feb 25, 2020 04:01 pm ET
GW Pharmaceuticals plc Reports Fourth Quarter and Year-End 2019 Financial Results and Operational Progress
GW Pharmaceuticals plc (Nasdaq: GWPH), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announces financial results for the fourth quarter and full-year ended December 31, 2019. “2019...
Feb 24, 2020 07:00 am ET
GW Pharmaceuticals to Present at the Cowen 40th Annual Healthcare Conference
GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that Justin Gover, GW’s Chief Executive Officer, will...
Feb 12, 2020 08:11 am ET
GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Fourth Quarter and Year Ending December 31, 2019 and Host Conference Call on February 25th, 2020
GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on February 25th,...
Feb 03, 2020 07:00 am ET
GW Pharmaceuticals and Greenwich Biosciences Submit Supplemental New Drug Application to U.S. FDA for Epidiolex® (cannabidiol) for the Treatment of Tuberous Sclerosis Complex
GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with its U.S. subsidiary Greenwich Biosciences, Inc., announced...
Jan 12, 2020 06:00 pm ET
GW Pharmaceuticals Pre-Announces Preliminary Unaudited Fourth Quarter and Full-Year 2019 Net Product Sales
GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and...
Jan 07, 2020 01:13 pm ET
GW Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference
GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that Justin Gover, GW’s Chief Executive Officer, will...
Dec 07, 2019 12:00 pm ET
Greenwich Biosciences, a GW Pharmaceuticals Company, Presents New Data for EPIDIOLEX® (cannabidiol) in Patients with Tuberous Sclerosis Complex (TSC) at the American Epilepsy Society Annual Meeting
GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S. subsidiary Greenwich Biosciences, today presented new data from a Phase 3 clinical...
Dec 05, 2019 07:00 am ET
GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences to Present Data on EPIDIOLEX® (cannabidiol) Oral Solution at the American Epilepsy Society Annual Meeting
GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S. subsidiary Greenwich Biosciences announced today that a variety of data, including...
Nov 22, 2019 07:00 am ET
GW Pharmaceuticals to Present at Upcoming Investor Conferences
GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that...
Nov 10, 2019 07:01 pm ET
GW Pharmaceuticals receives positive NICE recommendation for EPIDYOLEX® (cannabidiol) oral solution for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy
GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), world leader in discovering, developing and commercialising cannabinoid prescription medicines, today announces that two of its medicines, EPIDYOLEX (cannabidiol) oral...
Nov 05, 2019 04:00 pm ET
GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the Third Quarter Ended September 30, 2019
GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the discovery, development and commercialization of cannabinoid prescription medicines, announces financial results for the third quarter ended September 30,...
Oct 31, 2019 07:00 am ET
GW Pharmaceuticals to Present at Upcoming Investor Conferences
GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that...
Oct 09, 2019 07:00 am ET
GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Third Quarter Ending September 30, 2019 and Host Conference Call on November 5, 2019
GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on November 5th,...
Sep 24, 2019 12:38 pm ET
GW Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference on Wednesday, October 2nd, 2019
GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the development and commercialization of cannabinoid prescription medicines, today announced that Scott...
Sep 23, 2019 07:00 am ET
GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy
GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), world leader in discovering, developing and commercialising cannabinoid prescription medicines, today announces that the European Commission (EC) has approved the marketing...
Sep 04, 2019 08:22 am ET
GW Pharmaceuticals to Present at the Morgan Stanley 17th Annual Global Healthcare Conference on Wednesday, September 11th, 2019
GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that...
Aug 06, 2019 04:01 pm ET
GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2019
GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development and commercialization of cannabinoid prescription medicines, announces financial results for the second quarter ended June 30, 2019....
Jul 26, 2019 06:37 am ET
GW Pharmaceuticals receives positive CHMP opinion for EPIDYOLEX™ (cannabidiol oral solution) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy
GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), the world leader in discovering, developing and commercialising cannabinoid prescription medicines, today announced that the European Medicines Agency’s (EMA) Committee for...
Jul 23, 2019 01:27 pm ET
GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Period Ending June 30, 2019 and Host Conference Call on August 6, 2019
GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on August 6, 2019...
Jun 27, 2019 08:00 am ET
Adrian Rawcliffe to Succeed James Noble as Adaptimmune Chief Executive Officer
Adaptimmune Therapeutics plc (Nasdaq:ADAP) today announced that Adrian Rawcliffe, currently Chief Financial Officer (CFO) of the Company, will succeed James Noble as Chief Executive Officer (CEO). This transition will occur when James retires from...
Jun 04, 2019 06:42 am ET
GW Pharmaceuticals to Present at the 40th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 11th, 2019
GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that...
May 09, 2019 08:35 am ET
GW Pharmaceuticals to Present at the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 15, 2019
GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that...
May 06, 2019 04:01 pm ET
GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2019
GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development and commercialization of cannabinoid prescription medicines, announces financial results for the first quarter ended March 31, 2019....
May 06, 2019 04:01 pm ET
GW Pharmaceuticals Reports Positive Phase 3 Pivotal Trial Results for EPIDIOLEX® (cannabidiol) Oral Solution in Patients with Seizures Associated With Tuberous Sclerosis Complex
GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced...
May 02, 2019 07:00 am ET
GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences to Present Data on Epidiolex® (cannabidiol) oral solution, CV at the 2019 American Academy of Neurology Annual Meeting
GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), the world leader in the development and commercialization of cannabinoid prescription medicines, along with its U.S. subsidiary Greenwich Biosciences, will present data from...
Apr 23, 2019 01:40 pm ET
GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Period Ending March 31, 2019 and Host Conference Call on May 6, 2019
GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on May 6, 2019 its...
Apr 11, 2019 04:05 pm ET
GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences Announce Appointment of Darren Cline as U.S. Chief Commercial Officer
GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the development and commercialization of cannabinoid prescription medicines, today announced the appointment of Darren Cline as its new U.S. Chief Commercial...
Apr 03, 2019 08:00 am ET
Research Report Identifies Plug Power, Milacron, Genesis Healthcare, Jounce Therapeutics, GW Pharmaceuticals, and Earthstone Energy with Renewed Outlook — Fundamental Analysis, Calculating Forward Mov
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Plug Power, Inc. (NASDAQ:PLUG), Milacron Holdings Corp. (NYSE:MCRN),...
Mar 18, 2019 07:30 am ET
GW Pharmaceuticals plc Announces the Sale of Priority Review Voucher for $105M
GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the development and commercialization of cannabinoid prescription medicines, today announced that GW Research Ltd. has entered into a definitive agreement to...
Mar 14, 2019 08:55 am ET
Three of the Influential Health and Wellness Cannabis Companies
HOUSTON, TX / ACCESSWIRE / March 14, 2019 / Cannabis is quickly becoming one of the most industry-disruptive forces.
Feb 26, 2019 04:01 pm ET
GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the Quarter Ended December 31, 2018
GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the development and commercialization of cannabinoid prescription medicines, announces financial results for the quarter ended December 31, 2018. “We are...
Feb 26, 2019 11:08 am ET
GW Pharmaceuticals to Present at Upcoming Investor Conferences
GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the development and commercialization of cannabinoid prescription medicines, announced that Justin Gover, GW’s Chief Executive Officer, will present at the...
Feb 07, 2019 03:22 pm ET
GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Period Ending 31 December 2018 and Host Conference Call on 26 February 2019
GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 26 February,...
Jan 17, 2019 09:00 am ET
Mugglehead reveals a number of stocks set to take advantage of hemp
Hemp. It’s one of the world’s fastest growing plants—a separate species of the cannabis sativa genus that, due to its >0.3% tetrahydrocannabinol (THC) content, makes it literally almost impossible to get high from smoking it.But that’s not stopping...
Dec 31, 2018 07:00 am ET
GW Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference
GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that Justin...
Nov 29, 2018 07:30 am ET
Investor Expectations to Drive Momentum within ANSYS, Nordic American Tankers, Woodward, GW Pharmaceuticals, CareTrust REIT, and TOCAGEN INC — Discovering Underlying Factors of Influence
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ANSYS, Inc. (NASDAQ:ANSS), Nordic American Tankers Limited (NYSE:NAT),...
Nov 27, 2018 04:00 pm ET
GW Pharmaceuticals plc Reports Fiscal Fourth Quarter and Year-End 2018 Financial Results and Operational Progress
GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the development and commercialization of cannabinoid prescription medicines, announces financial results for the fourth quarter and year ended 30 September...
Nov 26, 2018 07:00 am ET
GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for EPIDIOLEX® (cannabidiol) oral solution CV in Patients with Dravet Syndrome
GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: “GWP,” “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform,...
Nov 19, 2018 04:05 pm ET
GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences to Present Data on EPIDIOLEX® (cannabidiol) Oral Solution at the American Epilepsy Society Annual Meeting
GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), the world leader in the development and commercialization of cannabinoid prescription medicines, along with its U.S. subsidiary Greenwich Biosciences, announced today that...
Nov 06, 2018 07:00 am ET
GW Pharmaceuticals to Report Fourth Quarter and Year-End Financial Results and Host Conference Call on 27 November, 2018
GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 27 November,...
Nov 01, 2018 06:45 am ET
EPIDIOLEX® (cannabidiol) Oral Solution – the First FDA-approved Plant-derived Cannabinoid Medicine – Now Available by Prescription in the U.S.
GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), the world leader in the development and commercialization of cannabinoid prescription medicines, along with its U.S. subsidiary Greenwich Biosciences, announced today that...
Oct 19, 2018 08:10 am ET
Investor Expectations to Drive Momentum within Motorola Solutions, Shire plc, Bitauto, GRIDSUM HOLDING, GW Pharmaceuticals, and Actinium Pharmaceuticals — Discovering Underlying Factors of Influence
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Motorola Solutions, Inc. (NYSE:MSI), Shire plc (NASDAQ:SHPG), Bitauto...
Oct 05, 2018 10:34 am ET
GW Pharmaceuticals plc Announces the Closing of Public Offering of ADSs, Raising Gross Proceeds of $345 Million and Full Exercise of Underwriters' Option to Purchase Additional ADSs
GW Pharmaceuticals plc (Nasdaq: GWPH, "GW," and the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the closing of...
Oct 02, 2018 08:04 pm ET
GW Pharmaceuticals plc Announces Pricing of Public Offering of ADSs Raising Gross Proceeds of $300 Million
GW Pharmaceuticals plc (Nasdaq: GWPH, "GW," and the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the pricing of...
Oct 01, 2018 04:01 pm ET
GW Pharmaceuticals Announces Proposed Public Offering of ADSs
GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform and whose U.S....
Sep 27, 2018 09:27 am ET
GW Pharmaceuticals plc and its U.S. Subsidiary Greenwich Biosciences Announce the DEA has Rescheduled EPIDIOLEX® (cannabidiol) Oral Solution to Schedule V
GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S....
Aug 07, 2018 04:01 pm ET
GW Pharmaceuticals plc Reports Fiscal Third Quarter 2018 Financial Results and Operational Progress
GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the development and commercialization of cannabinoid prescription medicines, announces financial results for the third quarter ended 30 June 2018. “The recent...
Jul 24, 2018 09:00 am ET
Cannabinoids May Do More Than Manage Cancer Symptoms -- CFN Media
CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, today announced publication of an article covering how cannabinoids are currently being used by physicians and how...
Jul 23, 2018 04:00 pm ET
GW Pharmaceuticals to Report Third Quarter Financial Results and Host Conference Call on 7 August, 2018
GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 7 August, 2018...
Jun 27, 2018 09:41 am ET
Isodiol International Inc. Applauds the FDA’s Decision to Recognize the Medical Benefits of CBD at Higher Concentrations and Announces Corporate Restructure
Isodiol International Inc. (CSE: ISOL) (OTC:ISOLF) (FSE: LB6A.F) (the “Company” or “Isodiol”), a global CBD innovator specializing in hemp-based health and wellness products, the development of pharmaceutical CBD delivery methods and the...
Jun 25, 2018 02:31 pm ET
GW Pharmaceuticals plc and its U.S. Subsidiary Greenwich Biosciences Announce FDA Approval of EPIDIOLEX® (cannabidiol) oral solution – the First Plant-derived Cannabinoid Prescription Medicine
GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S....
Jun 25, 2018 12:57 pm ET
GW Pharmaceuticals plc and its U.S. Subsidiary Greenwich Biosciences Announce FDA Approval of EPIDIOLEX® (cannabidiol) oral solution – the First Plant-derived Cannabinoid Prescription Medicine
GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S....
Jun 06, 2018 01:19 pm ET
GW Pharmaceuticals to Present at the Goldman Sachs 39th Annual Global Healthcare Conference
GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that GW...
Jun 06, 2018 08:25 am ET
Recent Analysis Shows Clementia Pharmaceuticals, Superior Group of Companies, ACM Research, Atlantic Capital Bancshares, Customers, and GW Pharmaceuticals Market Influences — Renewed Outlook, Key Driv
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Clementia Pharmaceuticals Inc. (NASDAQ:CMTA), Superior Group of Companies,...
May 16, 2018 05:00 pm ET
GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences Announce Publication in The New England Journal of Medicine of a Phase 3 Study of Epidiolex® (cannabidiol oral solution) in Lennox-Gastaut
GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S....
May 08, 2018 04:00 pm ET
GW Pharmaceuticals plc Reports Fiscal Second Quarter 2018 Financial Results and Operational Progress
GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces financial...
May 08, 2018 01:00 pm ET
GW Pharmaceuticals to Present at Bank of America Merrill Lynch 2018 Health Care Conference
GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that GW...
May 03, 2018 07:37 am ET
GW Pharmaceuticals to Report Second Quarter Financial Results and Host Conference Call on 8 May, 2018
GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 8 May, 2018 its...
Apr 19, 2018 12:45 pm ET
GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences Announces the Unanimous Positive Result of FDA Advisory Committee Meeting for First Plant-Based Pharmaceutical Cannabidiol Treatment for Se
LONDON and CARLSBAD, Calif., April 19, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW”, “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along...
Apr 12, 2018 07:30 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within Magic Software Enterprises, Tuniu, Visteon, Magna International, Eaton Corporation, and GW Pharmaceuticals — New Research Emphasizes
NEW YORK, April 12, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Magic Software Enterprises Ltd. (NASDAQ:MGIC), Tuniu...
Apr 12, 2018 07:00 am ET
Mar 16, 2018 08:20 am ET
Report: Developing Opportunities within Capital Product Partners, Adient, Arbutus Biopharma, GW Pharmaceuticals, Customers, and Laureate Education — Future Expectations, Projections Moving into 2018
NEW YORK, March 16, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Capital Product Partners L.P. (NASDAQ:CPLP), Adient...
Mar 13, 2018 04:01 pm ET
GW Pharmaceuticals Announces Receipt of Notices of Allowance by the United States Patent and Trademark Office (USPTO) for Five New Epidiolex® (cannabidiol) Patents
LONDON and CARLSBAD, Calif., March 13, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along...
Mar 05, 2018 12:36 pm ET
GW Pharmaceuticals to Present at the Cowen and Company 38th Annual Health Care Conference on 12 March
LONDON and CARLSBAD, Calif., March 05, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced...
Feb 27, 2018 07:00 am ET
GW Pharmaceuticals Receives Orphan Drug Designation from the European Medicines Agency (EMA) for Cannabidiol for the Treatment of Tuberous Sclerosis
LONDON and CARLSBAD, Calif., Feb. 27, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today...
Feb 21, 2018 04:01 pm ET
Feb 06, 2018 11:35 am ET
GW Pharmaceuticals to Present at the Leerink Partners 7th Annual Global Healthcare Conference on 14 February
LONDON and CARLSBAD, Calif., Feb. 06, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced...
Feb 05, 2018 04:00 pm ET
GW Pharmaceuticals Announces the European Medicines Agency (EMA) Accepts Epidiolex® (cannabidiol) Marketing Authorization Application (MAA) for Review
MAA seeking regulatory approval of Epidiolex for seizures associated with Lennox-Gastaut syndrome and Dravet syndrome
Feb 05, 2018 04:00 pm ET
GW Pharmaceuticals plc Reports Fiscal First Quarter 2018 Financial Results and Operational Progress
- Epidiolex® (cannabidiol) NDA and MAA applications accepted for review –- NDA PDUFA goal date scheduled for June 27, 2018 -- Conference call today at 4:30 p.m. EST -
Jan 29, 2018 01:00 pm ET
GW Pharmaceuticals to Report Q1 Financial Results and Host Conference Call on 5 February, 2018
LONDON, Jan. 29, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 5 February, 2018...
Jan 24, 2018 06:30 pm ET
GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences Announce Publication of Landmark Epidiolex® (cannabidiol) Study in The Lancet
– First well-controlled clinical study of cannabidiol in Lennox-Gastaut syndrome, a rare, severe, form of childhood-onset epilepsy that is difficult to treat –
Jan 08, 2018 10:06 am ET
Dec 29, 2017 07:00 am ET
GW Pharmaceuticals Submits Marketing Authorisation Application in Europe for Epidiolex® (cannabidiol) in the treatment of Lennox-Gastaut syndrome and Dravet syndrome
LONDON and CARLSBAD, Calif., Dec. 29, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced it...
Dec 28, 2017 07:00 am ET
GW Pharmaceuticals Announces Acceptance of NDA Filing for Epidiolex® (cannabidiol) in the treatment of Lennox-Gastaut syndrome and Dravet syndrome
LONDON and CARLSBAD, Calif., Dec. 28, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that...
Dec 21, 2017 07:00 am ET
GW Pharmaceuticals Announces the Appointment of Three New Independent Members to its Board of Directors
LONDON, Dec. 21, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced the appointment of three...
Dec 13, 2017 07:00 am ET
Dec 11, 2017 05:19 pm ET
GW Pharmaceuticals plc Announces the Closing of Public Offering of ADSs Raising Gross Proceeds of $317.4 Million and Full Exercise of Underwriter’s Option to Purchase Additional ADSs
LONDON, Dec. 11, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) ("GW" or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the closing of the...
Dec 06, 2017 09:40 pm ET
GW Pharmaceuticals plc Announces Pricing of Public Offering of ADSs Raising Gross Proceeds of $276 Million
LONDON, Dec. 06, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) ("GW" or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the pricing of an...
Dec 05, 2017 04:01 pm ET
GW Pharmaceuticals Announces Proposed Public Offering of ADSs
LONDON, Dec. 05, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) ("GW" or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today that it intends to...
Dec 04, 2017 07:00 am ET
GW Pharmaceuticals plc Reports Fiscal Fourth Quarter 2017 and Year-End Financial Results and Operational Progress
- Epidiolex® (cannabidiol) NDA Submitted to FDA -- Conference call today at 7:30 a.m. EST -
Nov 27, 2017 07:00 am ET
GW Pharmaceuticals to Report Q4 and Year-End Financial Results and Host Conference Call on 4 December, 2017
LONDON, Nov. 27, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 4 December, 2017...
Nov 22, 2017 07:00 am ET
GW Pharmaceuticals to Present at Upcoming Investor Conferences
– 29th Annual Piper Jaffray Healthcare Conference on November 29, 2017 –
Nov 21, 2017 07:00 am ET
GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences to Present Epidiolex® (cannabidiol) Data and Educational Programs at the American Epilepsy Society Annual Meeting
Over 20 abstracts released online today from Phase 3 programs in Lennox-Gastaut Syndrome and Dravet syndrome and from Expanded Access Program
Oct 11, 2017 10:00 am ET
For Early Success in Cannabis Look Outside the Box
LOS ANGELES, October 11, 2017 /PRNewswire/ --
Oct 10, 2017 10:55 am ET
Data Shows Positive Projections for the Legal Cannabis Industry
NEW YORK, October 10, 2017 /PRNewswire/ --
Aug 07, 2017 04:05 pm ET
GW Pharmaceuticals plc Reports Fiscal Third Quarter 2017 Financial Results and Operational Progress
- Epidiolex® NDA submission process underway - - Conference call today at 4:30 p.m. EDT -...
Jul 24, 2017 02:59 pm ET
GW Pharmaceuticals to Report Q3 Financial Results and Host Conference Call on 7 August, 2017
LONDON, July 24, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH), (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 7 August, 2017 its third quarter financial results for the period ending 30 June, 2017. GW will also host a conference call the same day at 4:30 p.m. EDT. Conference call information will be provided in the financial results press release. A replay of the call will also be available through the Company's website (www.gw...
Jul 17, 2017 02:15 pm ET
May 24, 2017 05:00 pm ET
GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences Announce Publication of Groundbreaking Study of Epidiolex® (cannabidiol) in The New England Journal of Medicine
Orrin Devinsky, M.D.Justin Gover– Pharmaceutical formulation of cannabidiol significantly reduced convulsive seizure frequency in children on multiple anti-epileptic drugs with poor seizure control –...
Feb 15, 2017 08:30 am ET
Feb 03, 2017 09:00 am ET
Spending on Legal Cannabis Accelerates
NEW YORK, February 3, 2017 /PRNewswire/ --
Dec 05, 2016 09:31 am ET
Covered Call reports for Exelixis, Alibaba, Procter & Gamble, Whiting Petroleum and GW Pharmaceuticals include trade ideas that offer returns of 20% or more!
CHICAGO, Dec. 5, 2016 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BABA, EXEL, GWPH, PG, and WLL.
Dec 01, 2016 06:15 am ET
GW Pharmaceuticals plc Announces Epidiolex® (cannabidiol) Data Presentations and Educational Programs at the American Society of Epilepsy Annual Meeting
-  Presentations include clinical results from Phase 3 programs in Lennox-Gastaut Syndrome and Dravet Syndrome, as well as additional independent reports from Epidiolex Expanded Access Program sites  -...
Nov 22, 2016 08:00 am ET
GW Pharmaceuticals to Present at the 28th Annual Piper Jaffray Healthcare Conference on 29 November
LONDON, Nov. 22, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW’s Chief Executive Officer, will present at the 28th Annual Piper Jaffray Healthcare Conference on Tuesday, 29 November 2016, at 10:30 a.m. ET at the Lotte New York Palace, New York City....
Nov 16, 2016 09:23 am ET
Cannabinoid Drug Advancements Take Off After Quantum Shift in U.S. Drug Policy
PALM BEACH, Florida, November 16, 2016 /PRNewswire/ --
Nov 11, 2016 08:30 am ET
The Expectations of the Legal Cannabis Market After Elections
NEW YORK, November 11, 2016 /PRNewswire/ --
Nov 08, 2016 09:31 am ET
InvestorsObserver releases covered-call reports for Disney, GW Pharmaceuticals, YY, CVS Caremark and Tenet Healthcare
CHICAGO, Nov. 8, 2016 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CVS, DIS, GWPH, THC, and YY.
Oct 25, 2016 09:00 am ET
New Report: U.S. CBD Sales to Reach $2.1B by 2020 With $450M From Hemp Industry
The Hemp Business Journal (HBJ), the hemp industry's authority on big data and market intelligence, has released The CBD Report showing cannabidiol as one of the fastest growing market categories in the U.S. hemp and legal marijuana industries with a compound annual growth rate of 59%.
Oct 14, 2016 10:31 am ET
InvestorsObserver releases covered-call reports for Netflix, JetBlue, GW Pharmaceuticals, Ulta Salon Cosmetics & Fragrance Inc. and Delta Airlines
CHICAGO, Oct. 14, 2016 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DAL, GWPH, JBLU, NFLX, and ULTA.
Sep 27, 2016 10:31 am ET
NVIDIA trade offers an 8% return in 53 days, or find similar option trades on GW Pharmaceuticals, Consol Energy, Micron, and Spark Therapeutics
CHICAGO, Sept. 27, 2016 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CNX, GWPH, MU, NVDA, and ONCE.
Sep 26, 2016 06:57 am ET
GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for Epidiolex® (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome
- Primary endpoint achieved in both Epidiolex doses with high statistical significance compared to placebo - ...
Sep 07, 2016 07:00 am ET
GW Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference
LONDON, Sept. 07, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW’s Chief Executive Officer, is scheduled to present at the Morgan Stanley Global Healthcare Conference to be held at the Grand Hyatt Hotel in New York City on Wednesday, 14 September 2016 at 9:55 a.m. EDT....
Aug 09, 2016 07:00 am ET
GW Pharmaceuticals plc Reports Third Quarter 2016 Financial Results and Operational Progress
- Positive Phase 3 Epidiolex pivotal trial in Lennox-Gastaut Syndrome (LGS) - - Positive FDA pre-NDA meeting - NDA for Dravet syndrome and LGS on track for H1 2017 submission -             -Conference call today at 8:30 a.m. EDT, 1:30 p.m. BST -...
Aug 02, 2016 07:00 am ET
GW Pharmaceuticals to Report Q3 Financial Results and Host Conference Call on 9 August, 2016
LONDON, Aug. 02, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 9 August, 2016 its third quarter financial results for the period ending 30 June, 2016. GW will also host a conference call the same day at 8:30 a.m. EDT (1:30 p.m. BST). Conference call information will be provided in the financial results press release. A replay of the call will also be available through the ...
Jul 18, 2016 11:15 am ET
GW Pharmaceuticals plc Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Raising $289.8 Million on the NASDAQ Global Market and Full Exercise of Underwriter’s Option t
LONDON, July 18, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the closing of the previously announced offering on the NASDAQ Global Market by GW of 2,800,000 of American Depositary Shares (ADSs) and the full exercise by the underwriters of their option to purchase 420,000 additional ADSs from GW at a price of $90.00 per ADS, raising gross proceeds of $289,800,000 (before d...
Jul 12, 2016 11:24 pm ET
GW Pharmaceuticals plc Announces Pricing of U.S. Public Offering of ADSs Raising $252.0 Million on NASDAQ Global Market
LONDON, July 12, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH), (AIM:GWP), ("GW" or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the pricing of an underwritten public offering by the Company. GW will issue 2,800,000 of American Depositary Shares (“ADSs”), representing 33,600,000 ordinary shares of GW, at a price to the public of $90.00 per ADS on the NASDAQ Global Market, raising gross proceeds of approximately $252,000,000 (before dedu...
Jul 12, 2016 04:01 pm ET
GW Pharmaceuticals Announces Proposed Public Offering of ADSs
LONDON, July 12, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today that it intends to sell, subject to market and other conditions, $150,000,000 of American Depositary Shares (“ADSs”) representing ordinary shares of GW on the NASDAQ Global Market in an underwritten U.S. public offering.  GW expects to grant the underwriters a 30-day option to purchase up to an additional $22,50...
Jun 27, 2016 07:00 am ET
GW Pharmaceuticals Announces Positive Phase 3 Pivotal Trial Results for Epidiolex® (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome
- Primary endpoint achieved with high statistical significance (p=0.0135) showing that Epidiolex treatment reduces drop seizures compared to placebo -...
Jun 21, 2016 07:00 am ET
GW Pharmaceuticals Announces New Planned Epidiolex (Cannabidiol or CBD) Development Program in Infantile Spasms (IS)
- Orphan Drug Designation Granted from FDA for Epidiolex for the Treatment of IS - ...
May 31, 2016 07:00 am ET
GW Pharmaceuticals to Present at the Goldman Sachs 37th Annual Global Healthcare Conference and the Jefferies 2016 Healthcare Conference
LONDON, May 31, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW’s Chief Executive Officer, is scheduled to present at the Goldman Sachs 37th Annual Global Healthcare Conference to be held at Terranea in Rancho Palos Verdes, California on 8 June, 2016 at 8:40 a.m. PDT and at the Jefferies 2016 Global Healthcare Conference at the Grand Hyatt Hotel in New Y...
May 16, 2016 07:00 am ET
GW Pharmaceuticals to Present at the 2016 UBS Global Healthcare Conference on 24 May
LONDON, May 16, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH), (AIM:GWP), (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW’s Chief Executive Officer, will present at the 2016 UBS Global Healthcare Conference on Tuesday, May 24, 2016, at 8:00 a.m. (EDT) at the Grand Hyatt Hotel in New York City.  ...
May 05, 2016 07:00 am ET
GW Pharmaceuticals plc Reports Second Quarter and Half-Year 2016 Financial Results and Operational Progress
- Positive Phase 3 Epidiolex pivotal trial in Dravet syndrome -- Initial LGS Phase 3 pivotal data expected in June -- Conference call today at 9:00 a.m. EDT, 2:00 p.m. BST -...
May 04, 2016 07:00 am ET
GW Pharmaceuticals to Present at the Bank of America Merrill Lynch 2016 Healthcare Conference on 10 May
LONDON, May 04, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW’s Chief Executive Officer, will present at the Bank of America Merrill Lynch 2016 Healthcare Conference on Tuesday, May 10, 2016, at 9:20 a.m. (PDT) at the Encore at the Wynn Las Vegas, Las Vegas, Nev.  ...
Apr 28, 2016 07:00 am ET
GW Pharmaceuticals to Report Q2, Half-Year Financial Results and Host Conference Call on 5 May, 2016
LONDON, April 28, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 5 May, 2016 its second quarter and half-year financial results for the period ending 31 March, 2016. GW will also host a conference call the same day at 9:00 a.m. EDT (2:00 p.m. BST). Conference call information will be provided in the financial results press release. A replay of the call will also be availabl...
Mar 15, 2016 10:31 am ET
Covered Call Alerts For Netflix, GW Pharmaceuticals, Sarepta Therapeutics, General Electric and Whole Foods Market Released By InvestorsObserver
CHICAGO, March 15, 2016 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NFLX, GWPH, SRPT, GE and WFM.To see the high-return covered-call trades uncovered by InvestorsObserver's analysts, read the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. (Note: You may have to copy this link into your browser then press the [ENTER] key.)NFLX: http://www.investorsobserver.com/pr/31420160/NFLX GWPH: http://www.investorsobserver.com/pr/31420160/GWPH SRPT: http://www.investorsobserver.com/pr/31420160/SRPT GE: http://www.investorsobserver.com/pr/31420160/GE
Mar 10, 2016 12:26 pm ET
SHAREHOLDER ALERT: Law Office of Brodsky & Smith, LLC Announces Investigation of GW Pharmaceuticals plc - GWPH
BALA CYNWYD, Pa., March 10, 2016 /PRNewswire/ -- Law Office of Brodsky & Smith, LLC announces an investigation of GW Pharmaceuticals plc ("GW Pharmaceuticals" or the "Company") (Nasdaq -GWPH- News) for potential violations of federal securities laws and breaches of the GW Pharamceuticals Board's fiduciary duties.
Mar 09, 2016 10:00 am ET
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against GW Pharmaceuticals PLC (GWPH) and Lead Plaintiff Deadline: March 21, 2016
NEW YORK, March 9, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a securities class action has been filed in the United States District Court of the Southern District of New York, docketed under 16-cv-00472, against GW Pharmaceuticals PLC ("GW Pharmaceuticals" or "the Company") (Nasdaq: GWPH), and certain of its officers, on behalf of a class consisting of all persons or entities who purchased GW Pharmaceuticals  securities between December 4, 2014 and January 8, 2016 inclusive (the "Class Period").
Mar 07, 2016 10:46 am ET
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notify Investors of Class Action Lawsuit Involving GW Pharmaceuticals plc and a Lead Plaintiff Deadline of March 21, 2016 - GWPH
NEW YORK, March 7, 2016 /PRNewswire/ -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased GW Pharmaceuticals plc (Nasdaq: GWPH) securities between December 4, 2014 and January 8, 2016.
Feb 23, 2016 12:37 pm ET
Covered Call Alerts For Starbucks, Caterpillar Inc., GW Pharmaceuticals, United Technologies and Synaptics Incorporated Released By InvestorsObserver
CHICAGO, Feb. 23, 2016 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SBUX, CAT, GWPH, UTX and SYNA.
Feb 19, 2016 02:47 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in GW Pharmaceuticals plc of Class action Lawsuit and Upcoming Deadline - GWPH
NEW YORK, Feb. 19, 2016 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against GW Pharmaceuticals plc ("GW Pharmaceuticals" or the "Company") (NASDAQ: GWPH) and certain of its officers.  The class action, filed in United States District Court, Southern District of New York, and docketed under 16-cv-00472, is on behalf of a class consisting of all persons or entities who purchased GW Pharmaceuticals securities between December 4, 2014 and January 8, 2016 inclusive (the "Class Period").  This class action seeks to recover damages against Defendants for alleg
Feb 09, 2016 01:44 pm ET
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In GW Pharmaceuticals plc To Contact The Firm Before Lead Plaintiff Deadline
NEW YORK, Feb. 9, 2016 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in GW Pharmaceuticals plc ("GW Pharmaceuticals" or the "Company") (NasdaqGM:GWPH) of the March 21, 2016 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers.
Feb 09, 2016 09:31 am ET
Covered Call Alerts For Starbucks, GW Pharmaceuticals, Supernus Pharmaceuticals, CSX and SunEdison Released By InvestorsObserver
CHICAGO, Feb. 9, 2016 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SBUX, GWPH, SUPN, CSX and SUNE.
Jan 27, 2016 04:11 pm ET
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in GW Pharmaceuticals plc to Contact the Firm Before Lead Plaintiff Deadline
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in GW Pharmaceuticals plc ("GW Pharmaceuticals" or the "Company") (NASDAQ: GWPH) of the March 21, 2016 deadline to seek the role of lead plaintiff in a federal...
Jan 26, 2016 09:31 am ET
Covered Call Alerts For Micron, Alibaba, GW Pharmaceuticals, Peabody Energy and Microsoft Released By InvestorsObserver
CHICAGO, Jan. 26, 2016 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MU, BABA, GWPH, BTU and MSFT.
Jan 22, 2016 05:00 pm ET
Bernstein Liebhard LLP Announces That A Suit Has Been Filed Against GW Pharmaceuticals plc
NEW YORK, Jan. 22, 2016 /PRNewswire/ -- Bernstein Liebhard LLP today announced that a securities class action has been filed in the United States District Court for the Southern District of New York on behalf of a class (the "Class") consisting of all persons or entities who purchased GW Pharmaceuticals plc ("GW Pharmaceuticals" or the "Company") (GWPH) American Depository Receipts ("ADRs") between December 4, 2014 and January 8, 2016 (the "Class Period").  The complaint charges GW Pharmaceuticals and certain of its officers with violations of the Securities Exchange Act of 1934. 

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.